The only diagnostics center built from the ground up by a robotics company, we combine automation with proprietary assay development to innovate molecular diagnostics faster than any other provider
End-to-end diagnostics automation means less staff, operational, & logistical resource spend for hospitals, with annual operational cost savings of $12M
Rapid test results allow a larger number of patients to be tested and treated. Overall cost-of-care reduced more than $8,000 per patient relative to batch testing
Reduce in-hospital foot traffic & resource use
98% sensitivity (95%CI 3), 1% higher than market leader. 3% higher than industry average
99% specificity. Logistics & specimen flexibility including built-in nasal qualifier. CT values available for all panels on request
13% reduction in antibiotic therapy duration. ICU patients had a 10% increase in survival rate compared to batch testing (Martinez, et al. Clinical Virology Symposium. 2016)
FirmaLab is legally certified to run overflow COVID-19 testing under P4 Clinical’s CLIA certification.
**Small Panel** 1. SARS COV-2 2. Influenza A 3. Influenza B 4. Respiratory Syncytial Virus **Large Panel ** *Virus* 1. Adenovirus 2. Coronavirus NL63 3. Coronavirus OC43 4. Coronavirus 229E 5. Metapneumovirus A/B 6. Rhinovirus/Enterovirus 7. Influenza Pan A (including Influenza A, Influenza A Subtypes H1, and Influenza A Subtypes H3) 8. Influenza B 9. Parainfluenza Virus 1 10. Parainfluenza Virus 2 11. Parainfluenza Virus 3 12. Parainfluenza Virus 4 13. Respiratory Syncytial Virus 14. SARS COV-2 *Bacteria* 1. Bordetella parapertussis 2. Bordetella pertussis 3. Chlamydia pneumoniae 4. Mycoplasma pneumoniae
Small panel (RP1) is part number 21000016. Large panel (RP2) is 21000001.
FirmaLab has labs in New York City and Washington D.C. and will soon be opening labs in Los Angeles and Seattle. FirmaLab is exploring opening additional labs across the country.